Cancer Genetics, Inc. (CGIX) financial statements (2020 and earlier)

Company profile

Business Address 201 ROUTE 17 NORTH
RUTHERFORD, NJ 07070
State of Incorp. DE
Fiscal Year End December 31
SIC 8071 - Medical Laboratories (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments201010192649
Cash and cash equivalents201010192649
Receivables271112752
Inventory, net of allowances, customer advances and progress billings 000000
Inventory 000000
Prepaid expense     11
Disposal group, including discontinued operation1      
Other current assets1232211
Other undisclosed current assets7(0)(0)(0)(0)(1)(1)
Total current assets:1392323283252
Noncurrent Assets
Property, plant and equipment1465641
Long-term investments and receivables     11
Long-term investments     11
Accounts and financing receivable, after allowance for credit loss      0
Intangible assets, net (including goodwill)     30
Goodwill     3 
Intangible assets, net (excluding goodwill)     10
Deposits noncurrent assets     00
Restricted cash and investments     60
Other noncurrent assets822231415112
Other undisclosed noncurrent assets     (11)(2)
Total noncurrent assets:826291921153
TOTAL ASSETS:21355242494755
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:31398842
Accrued liabilities    00 
Other undisclosed accounts payable and accrued liabilities31398732
Deferred revenue2
Debt311102106
Derivative instruments and hedges, liabilities 0     
Due to related parties 1     
Disposal group, including discontinued operation3      
Deferred revenue and credits11110
Contract with customer, liability2
Other undisclosed current liabilities20     
Total current liabilities:132720111049
Noncurrent Liabilities
Long-term debt and lease obligation0 13560
Long-term debt, excluding current maturities   356 
Finance lease, liability0
Capital lease obligations 10000
Operating lease, liability0
Liabilities, other than long-term debt1153121
Deferred revenue and credits11110
Accounts payable and accrued liabilities 0     
Contract with customer, liability0
Due to related parties1      
Other liabilities     1 
Derivative instruments and hedges, liabilities0042001
Other undisclosed noncurrent liabilities 0     
Total noncurrent liabilities:1166681
Total liabilities:13292517161310
Stockholders' equity
Stockholders' equity attributable to parent, including:772726333545
Common stock 000000
Additional paid in capital172164162140131113107
Accumulated other comprehensive income (loss)(0)00    
Accumulated deficit(164)(158)(135)(114)(98)(78)(61)
Warrants and rights outstanding     01
Other undisclosed stockholders' equity attributable to parent     (0)(1)
Total stockholders' equity:772726333545
TOTAL LIABILITIES AND EQUITY:21355242494755

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues1727292718107
Cost of revenue(10)(19)(18)(17)(14)(8)(5)
Gross profit:791110422
Operating expenses(18)(31)(30)(27)(25)(21)(10)
Operating loss:(11)(22)(19)(17)(21)(19)(8)
Nonoperating income (expense)(3)2(4)100(5)
Investment income, nonoperating14(2)2005
Other nonoperating expense(0)(0)(0)(0)   
Interest and debt expense(3)(2)(0)(0)(0)(0)(9)
Loss from continuing operations before equity method investments, income taxes:(18)(22)(23)(16)(22)(19)(22)
Income (loss) from equity method investments0    (1)(0)
Other undisclosed income from continuing operations before income taxes1      
Loss from continuing operations before income taxes:(17)(22)(23)(16)(22)(20)(22)
Income tax benefit1 2 121
Loss from continuing operations:(16)(22)(21)(16)(21)(18)(22)
Income from discontinued operations4      
Net loss:(13)(22)(21)(16)(21)(18)(22)
Other undisclosed net income attributable to parent3200019
Net loss attributable to parent:(10)(20)(21)(16)(20)(17)(12)
Other undisclosed net loss available to common stockholders, basic    (0)(0)(5)
Net loss available to common stockholders, diluted:(10)(20)(21)(16)(20)(17)(17)

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss:(13)(22)(21)(16)(21)(18)(22)
Other comprehensive income0      
Other undisclosed comprehensive income0      
Comprehensive loss:(13)(22)(21)(16)(21)(18)(22)
Other undisclosed comprehensive income, net of tax, attributable to parent220    
Comprehensive loss, net of tax, attributable to parent:(10)(20)(21)(16)(21)(18)(22)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: